IP Group plc's (IPO.L) portfolio company Istesso provided an update on the Phase 2b study of leramistat in rheumatoid arthritis. The study did not meet the primary endpoint of improvements in ACR20 compared to placebo. However, significant improvements were observed in the key secondary endpoint of bone erosions, as well as improvements in disability and fatigue in patients treated with leramistat.
According to Istesso, results reinforced leramistat's novel mechanism of action (MOA) and effectiveness in bone protection in people living with rheumatoid arthritis (RA). The results support further evaluation of leramistat's potential to promote tissue repair in rheumatoid arthritis, as well as other chronic conditions.
The leramistat phase 2b study was a 12-week randomised, double-blind, placebo-controlled trial in adults with moderate-severe rheumatoid arthritis and an inadequate response to treatment with methotrexate.
Istesso will publish full study results in due course and plans further Phase 2 studies to evaluate leramistat's unique potential to promote adaptive tissue repair in rheumatoid arthritis, as well as other chronic conditions. Istesso is sufficiently funded to conduct these studies.
IP Group said it has an undiluted holding of 56.5% in Istesso and anticipates providing a further update on Istesso, including its valuation, in its 2024 results that will be published next month.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.